ROIV is trading at $33.58 (4.24% up) following a strong follow-through from the prior session and continued optimism around recent company developments.
- Sentiment remains constructive following a settlement with Moderna and positive progress on the IMVT-1402 and brepocitinib pipelines.
- While broader markets are trending higher, the move is primarily driven by biotech-specific enthusiasm rather than general index strength.